Cognition Therapeutics wins patent for zervimesine through 2045
The United States Patent and Trademark Office has granted Cognition Therapeutics a patent covering a novel crystalline form, or polymorph, of zervimesine (CT1812), U.S. Patent No. 12,759,979, with a natural expiration in 2045 and potential eligibility for up to a five-year extension upon FDA approva
<p>The United States Patent and Trademark Office has granted Cognition Therapeutics a patent covering a novel crystalline form, or polymorph, of zervimesine (CT1812), U.S. Patent No. 12,759,979, with a natural expiration in 2045 and potential eligibility for up to a five-year extension upon FDA approva</p>